AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Pharma, Biotech and Diagnostics Joint Venture Partnering Terms and Agreements Directory 2019 - ResearchAndMarkets.com

April 3, 2019

DUBLIN--(BUSINESS WIRE)--Apr 3, 2019--The “Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019” report has been added to ResearchAndMarkets.com’s offering.

The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.

There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.

Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. In the event that the licensor does not commercialize the project, they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.

Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.

The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all joint venture deals announced since 2014 as recorded in the deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Key benefits

  • In-depth understanding of joint venture partnering deal trends since 2014
  • Analysis of the structure of joint venture agreements with numerous real life case studies
  • Comprehensive listing of all joint venture deals since 2014, together with deal terms, value and press release
  • Comprehensive access to actual joint venture contracts entered into by the world’s life science companies
  • Insight into the terms included in a joint venture agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Trends in joint venture dealmaking in the biopharma industry since 2014
  • Analysis of joint venture deal structure
  • Case studies of real-life joint venture deals
  • Comprehensive listing of joint venture deals since 2014
  • Access to joint venture contract documents
  • The leading joint venture deals by value since 2014
  • Most active joint venture dealmakers since 2014
  • The leading joint venture partnering resources

Available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in joint venture partnerships

2.1. Introduction

2.2. Definition of joint venture deals

2.3. Success factors for joint venture partnerships

2.4. When joint venture partnerships can be useful

2.5. Attributes of joint venture partnerships

2.6. Aligning partners to make the joint venture work

2.7. Trends in joint venture partnerships since 2014

2.7.1. Joint venture dealmaking by year, 2014 to 2019

2.7.2. Joint venture dealmaking by stage of development 2014 to 2019

2.7.3. Joint venture dealmaking by industry sector 2014 to 2019

2.7.4. Joint venture dealmaking by therapy area, 2014 to 2019

2.7.5. Joint venture dealmaking by technology type, 2014 to 2019

2.7.6. Joint venture dealmaking by most active company, 2014 to 2019

2.8. The future of joint venture partnerships

Chapter 3 - Overview of joint venture deal structure

3.1. Introduction

3.2. Joint venture agreement structure

3.3. Example joint venture agreements

3.3.1. Case study 1: Agila Specialties - Pfenex

3.3.2. Case study 2: Dance Biopharm - Harmony Asset

Chapter 4 - Leading joint venture deals

4.1. Introduction

4.2. Top joint venture deals by value

Chapter 5 - Top 50 most active joint venture dealmakers

5.1. Introduction

5.2. Top 50 most active joint venture dealmakers

Chapter 6 - Joint venture deals including contracts directory

6.1. Introduction

6.2. Joint venture deals with contracts 2014 to 2019

Appendices

Appendix 1 - Joint venture dealmaking by companies A-Z

Appendix 2 - Joint venture dealmaking by industry sector

Appendix 3 - Joint venture dealmaking by stage of development

Appendix 4 - Joint venture dealmaking by therapy area

Appendix 5 - Joint venture dealmaking by technology type

Appendix 6 - Joint venture references

Appendix 7 - Resources

Appendix 8 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/xf5b26/global_pharma?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190403005641/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biotechnology,Pharmaceuticals,Diagnostics

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/03/2019 11:14 AM/DISC: 04/03/2019 11:14 AM

http://www.businesswire.com/news/home/20190403005641/en